Physician profile
Matthew Nutaitis
NPI 1548240740
$11,358.79
in general payments reported to CMS, 2019-2025
27 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 81% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $493 · 2021: $863 · 2022: $1,585 · 2023: $2,215 · 2024: $2,771 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,673.77 | 2022-2025 | |
| New World Medical,INC. | $1,730.67 | 2023-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Alcon Vision LLC | $1,424.19 | 2019-2025 | Clareon, Hydrus Microstent, Unity |
| Glaukos Corporation | $778.79 | 2019-2025 | Idose, Idosetr |
| Allergan, INC. | $619.79 | 2019-2022 | |
| Sight Sciences, INC. | $570.89 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $522.13 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Aerie Pharmaceuticals, INC. | $450.74 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $375.06 | 2019-2021 | |
| Dompe US, INC. | $327.06 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $238.87 | 2022-2025 | Envista Mx60 Iol |
| Carl Zeiss Meditec USA, INC. | $156.16 | 2024 | Quatera 700 |
| Tarsus Pharmaceuticals, INC. | $152.47 | 2024 | |
| Mallinckrodt Hospital Products INC. | $143.78 | 2020-2021 | |
| Alimera Sciences, INC. | $139.37 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $136.97 | 2023 | Vabysmo |
| Omeros Corporation | $131.10 | 2019-2020 | |
| Axogen | $121.30 | 2023 | Avance Nerve Graft |
| Sun Pharmaceutical Industries INC. | $119.21 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $114.15 | 2024 | Eylea Hd |
| Horizon Therapeutics Plc | $113.27 | 2022 | |
| Ocular Therapeutix, INC. | $113.00 | 2019 | |
| Genentech USA, INC. | $105.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.40 | 2021 | |
| Carl Zeiss Meditec Cataract Technology INC. | $32.30 | 2022 | |
| Biotissue Holdings INC. | $20.83 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nutaitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.